Funding for this research was provided by:
National Cancer Institute (P20 CA233307, CA006695, K12CA139160)
Article History
Received: 28 March 2020
Accepted: 17 June 2020
First Online: 3 July 2020
Compliance with ethical standards
:
: Dr. Olopade disclosed stock ownership in Tempus and CancerIQ.